Estudio de las subfracciones lipoproteicas tras el tratamiento de simvastatina y ezetimiba, en monoterapia o combinado, en pacientes hiperlipidémicos

The coadministration of simvastatin and ezetimibe has an additive cholesterol-lowering effect. Furthermore, only simvastatin reduces atherogenic lipoprotein subfractions and exerts anti-inflammatory effects over longer periods of time.